Table 4.
Analysis of associations between IL10-1082A/G, -819C/T and -592C/A polymorphisms and risk of HAM/TSP development
| Polymorphisms | HAM/TSP | AC | Crude | ||
|---|---|---|---|---|---|
| n (%) | n (%) | OR (IC:95%) | p-value | Corrected p-value | |
| IL10-1082G/A | |||||
| A/A (low) | 20 (32.3) | 38 (53.5) | 1 | ||
| G/A (intermediate) | 34 (54.8) | 24 (33.8) | 2.69 (1.28–5.79) | ||
| G/G (high) | 8 (12.9) | 9 (12.7) | 1.69 (0.56–5.1) | 0.07 | 0.21 |
| A/A | 20 (32.3) | 38 (53.5) | 1 | ||
| G/A G/G | 42 (67.7) | 33 (46.5) | 2.42 (1.2–4.97) | 0.01 | 0.07 |
| Alleles | |||||
| A | 74 (59.7) | 100 (70.4) | 1 | ||
| G | 50 (40.3) | 42 (29.6) | 1.61 (0.97–2.70) | 0.07 | 0.21 |
| IL10–819/−592 a | |||||
| C/C and C/C | 25 (43.3) | 29 (40.8) | 1 | ||
| C/T and C/A | 31 (50.0) | 27 (38.0) | 1.33 (0.63–2.8) | ||
| T/T and A/A | 6 (9.7) | 15 (21.2) | 0.46 (0.15–1.33) | 0.38 | 1 |
| C/C and C/C | 25 (40.3) | 29 (40.8) | 1 | ||
| C/T + T/T and C/A + A/A | 37 (59.7) | 42 (59.2) | 1.02 (0.51–2.05) | 1 | 1 |
| T/T and A/A | 6 (9.7) | 15 (21.2) | 1 | ||
| C/C + C/T and C/C + C/A | 56 (90.3) | 56 (78.8) | 2.5 (0.94–7.44) | 0.12 | 0.84 |
| Phenotype | |||||
| ACC/ACC, ACC/ATA, ATA/ATA (Low) | 20 (32.3) | 38 (53.5) | 1 | ||
| GCC/ACC, GCC/ATA (Intermediate) | 34 (54.8) | 24 (33.8) | 2.69 (1.28–5.79) | ||
| GCC/GCC (High) | 8 (12.9) | 9 (12.7) | 1.69 (0.56–5.10) | 0.07 | 0.21 |
HAM/TSP HTLV-1 associated myelopathy tropical spastic paraparesis, Asymptomatic HTLV-1 patients, OR odds ration with confident interval, Chi-square 2 × 2 or 3 × 2 contingent tables, Fisher exact or Cochran-Armitage tests
a-819 and -592 are in linkage disequilibrium